Core Insights - Federal Realty Investment Trust (FRT) reported revenue of $311.52 million for the quarter ended June 2025, reflecting a 5.2% increase year-over-year and a surprise of +0.27% over the Zacks Consensus Estimate of $310.7 million [1] - Earnings per share (EPS) for the quarter was $1.91, compared to $1.32 in the same quarter last year, resulting in an EPS surprise of +10.4% against the consensus estimate of $1.73 [1] Revenue Breakdown - Mortgage interest income was reported at $0.28 million, matching the average estimate from five analysts, with no change year-over-year [4] - Rental income from percentage rents was $3.35 million, which is -14.8% lower than the average estimate of $4.47 million from three analysts [4] - Other lease-related rental income was $5.02 million, significantly below the average estimate of $8.67 million, representing a year-over-year decline of -64.7% [4] - Total rental income was $302.48 million, slightly below the average estimate of $305.89 million, showing a year-over-year increase of +2.3% [4] - Cost reimbursement rental income was $59.27 million, compared to the average estimate of $60.46 million, reflecting a year-over-year increase of +6.5% [4] Stock Performance - Over the past month, shares of Federal Realty Investment Trust have returned -0.8%, while the Zacks S&P 500 composite has changed by +0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Valvoline reported $439 million in revenue for the quarter ended June 2025, a year-over-year increase of 4.2% [1] - The EPS for the same period was $0.47, compared to $0.45 a year ago, with a surprise of +2.17% against the consensus estimate of $0.46 [1] - The revenue exceeded the Zacks Consensus Estimate of $435.64 million, resulting in a surprise of +0.77% [1] Financial Performance Metrics - Same-store sales growth was 4.9%, slightly below the estimated 5.2% by analysts [4] - System-wide franchised stores totaled 1,141, compared to the average estimate of 1,148 [4] - Total system-wide stores reached 2,124, slightly below the average estimate of 2,126 [4] - Same-store sales growth for company-operated stores was 4.2%, below the estimated 5.2% [4] - Same-store sales growth for franchised stores was 5.4%, compared to the estimated 5.7% [4] - Company-operated stores numbered 983, slightly above the average estimate of 978 [4] - Franchised stores opened totaled 19, compared to the estimated 20 [4] - Company-operated stores opened were 19, below the estimated 28 [4] Stock Performance - Valvoline's shares have returned -7% over the past month, while the Zacks S&P 500 composite increased by +0.5% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - AMC Entertainment is expected to report a quarterly loss of -$0.04 per share, reflecting a year-over-year increase of 90.7% in losses [1] - Revenue projections for AMC are set at $1.35 billion, which represents a 30.8% increase compared to the same quarter last year [1] - Analysts have revised their consensus EPS estimate downward by 255.6% over the past 30 days, indicating a significant reassessment of the company's financial outlook [1] Revenue Estimates - Analysts predict 'Revenues- Food and beverage' will reach $477.15 million, showing a year-over-year change of +30% [3] - The estimated 'Revenues- Other theatre' is projected at $122.88 million, indicating a year-over-year change of +24% [4] - 'Revenues- Admissions' is expected to be $748.23 million, reflecting a change of +32.6% from the prior-year quarter [4] Stock Performance - Over the past month, AMC Entertainment shares have recorded a return of -2.1%, while the Zacks S&P 500 composite has seen a +0.5% change [4] - AMC holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the upcoming period [4]

Core Insights - American Healthcare REIT (AHR) is expected to report quarterly earnings of $0.40 per share, reflecting a 21.2% increase year over year [1] - Analysts forecast revenues of $544.78 million, indicating an 8% year-over-year growth [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting analysts' reassessment of projections [1] Revenue Estimates - Analysts predict 'Revenues- Resident fees and services' to be $513.45 million, representing a 12.1% year-over-year increase [4] - 'Revenues- Real estate revenue' is estimated at $42.34 million, indicating a 9.1% decline from the previous year [4] Company Performance - Depreciation and amortization is expected to be $41.41 million according to analysts [4] - AHR shares have increased by 12.2% in the past month, outperforming the Zacks S&P 500 composite, which rose by 0.5% [4] - AHR holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near term [4]

Core Insights - UWM Holdings Corporation (UWMC) is expected to report quarterly earnings of $0.06 per share, reflecting a 50% increase year over year [1] - Analysts forecast revenues of $729.74 million, indicating a year-over-year increase of 43.9% [1] Earnings Estimates - The consensus EPS estimate has been revised 1.5% higher in the last 30 days, showing analysts' reevaluation of their initial estimates [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Projections - Revenue from loan production income is projected to reach $423.11 million, representing an 18.5% year-over-year increase [5] - Revenue from interest income is estimated at $125.34 million, indicating a 3.3% increase from the prior-year quarter [5] - Revenue from loan servicing income is expected to be $182.56 million, reflecting a year-over-year change of 26.9% [5] Stock Performance - UWM shares have increased by 4.8% in the past month, outperforming the Zacks S&P 500 composite, which saw a 0.5% increase [6] - UWM currently holds a Zacks Rank 5 (Strong Sell), suggesting expected underperformance relative to the overall market in the near term [6]

Core Insights - Douglas Emmett (DEI) reported revenue of $252.43 million for the quarter ended June 2025, marking a year-over-year increase of 2.7% and exceeding the Zacks Consensus Estimate of $251.14 million by 0.52% [1] - The company's earnings per share (EPS) for the same period was $0.37, a significant increase from $0.06 a year ago, aligning with the consensus EPS estimate [1] Revenue Breakdown - Total multifamily revenues reached $49.62 million, surpassing the average estimate of $48.48 million by analysts, reflecting a year-over-year change of 6.6% [4] - Total office revenues amounted to $202.81 million, slightly above the average estimate of $201.8 million, with a year-over-year increase of 1.8% [4] Stock Performance - Over the past month, shares of Douglas Emmett have returned -3.3%, contrasting with the Zacks S&P 500 composite's increase of 1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Myriad Genetics reported revenue of $213.1 million for the quarter ended June 2025, marking a year-over-year increase of 0.8% and exceeding the Zacks Consensus Estimate of $201.9 million by 5.55% [1] - The company achieved an EPS of $0.05, which is consistent with the EPS from the same period last year, and delivered a significant EPS surprise of 600% compared to the consensus estimate of -$0.01 [1] Revenue Breakdown by Core Product - Prenatal revenue reached $47.6 million, slightly below the average estimate of $49.93 million, reflecting a year-over-year increase of 10.7% [4] - Hereditary Cancer revenue was $96.3 million, surpassing the average estimate of $88.37 million, with a year-over-year growth of 5.3% [4] - Pharmacogenomics revenue totaled $37.8 million, exceeding the average estimate of $32.08 million, but showing a year-over-year decline of 12.1% [4] - Tumor Profiling revenue was reported at $31.4 million, closely aligning with the average estimate of $31.31 million, and indicating a year-over-year decrease of 3.7% [4] Stock Performance - Myriad's shares have declined by 24.8% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - NNN REIT reported revenue of $226.5 million for the quarter ended June 2025, reflecting a year-over-year increase of 4.8% and surpassing the Zacks Consensus Estimate of $225.55 million by 0.42% [1] - The company's EPS for the quarter was $0.85, compared to $0.58 in the same quarter last year, indicating a significant improvement and an EPS surprise of 1.19% over the consensus estimate of $0.84 [1] Revenue Breakdown - Rental income was reported at $226.5 million, exceeding the four-analyst average estimate of $225.07 million, with a year-over-year change of +4.8% [4] - Interest and other income from real estate transactions was reported at $0.3 million, which fell short of the three-analyst average estimate of $0.59 million, representing a year-over-year decline of 54.8% [4] Stock Performance - Over the past month, shares of NNN REIT have returned -0.7%, while the Zacks S&P 500 composite has increased by 1% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance against the broader market in the near term [3]

Core Insights - Analysts project Royalty Pharma (RPRX) will report quarterly earnings of $1.10 per share, reflecting a 14.6% year-over-year increase [1] - Revenue is expected to reach $686.22 million, marking a 12.9% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Revenue Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' is projected to reach $206.12 million, a 5.8% increase year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is estimated at $53.90 million, indicating a 15.6% decrease from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is expected to be $39.81 million, reflecting a 19% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is forecasted at $42.75 million, a 10.7% increase year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is anticipated to reach $39.51 million, showing a 29.5% increase from the previous year [5] Additional Product Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' is projected at $19.64 million, a 17.3% increase year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is expected to be $31.21 million, indicating a 25.2% increase from the prior year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is forecasted at $10.87 million, reflecting a 4.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $57.04 million, indicating a 17.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is projected to reach $38.47 million, reflecting a 28.6% increase year-over-year [8] Stock Performance - Shares of Royalty Pharma have increased by 6.4% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 1% [8] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [8]

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of -$1.30 per share in its upcoming release, pointing to a year-over-year increase of 33%. It is anticipated that revenues will amount to $103.42 million, exhibiting an increase of 14.5% compared to the year-ago quarter. The current level reflects a downward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their i ...